| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium.
Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clinical evidence supporting the therapy's efficacy and cost-effectiveness and ensures broader access for Belgian patients.
"The reimbursement of gammaCore by RIZIV / INAMI is a remarkable step forward for patients suffering from cluster headaches in Belgium," said Prof. Paemeleire, leading the Headache Clinic of the Neurology Department at Ghent University Hospital. "This decision reflects the growing recognition of the clinical and economic benefits of non-invasive vagus nerve stimulation. As a healthcare provider, I am pleased that this reimbursement will now allow more patients to access a therapy that can significantly improve their daily lives while contributing to a more sustainable healthcare system."
Posted In: ECOR
